<!DOCTYPE html>
<html lang="de">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Morbus Fabry - Teil 4: Therapie & Management</title>
    <style>
        @import url('https://fonts.googleapis.com/css2?family=Inter:wght@300;400;500;600;700&display=swap');
        
        * {
            margin: 0;
            padding: 0;
            box-sizing: border-box;
        }
        
        :root {
            --primary-color: #667eea;
            --secondary-color: #764ba2;
            --accent-color: #f093fb;
            --success-color: #4facfe;
            --warning-color: #fa709a;
            --danger-color: #ff6b6b;
            --info-color: #74b9ff;
            --text-primary: #2d3748;
            --text-secondary: #4a5568;
            --text-muted: #718096;
            --bg-white: #ffffff;
            --bg-light: #f8fafc;
            --bg-lighter: #f1f5f9;
            --border-radius: 16px;
            --border-radius-lg: 24px;
            --spacing-xs: 8px;
            --spacing-sm: 16px;
            --spacing-md: 24px;
            --spacing-lg: 32px;
            --spacing-xl: 48px;
            --shadow-sm: 0 4px 6px -1px rgba(0, 0, 0, 0.1);
            --shadow-md: 0 10px 15px -3px rgba(0, 0, 0, 0.1);
            --shadow-lg: 0 20px 25px -5px rgba(0, 0, 0, 0.1);
        }
        
        body {
            font-family: 'Inter', -apple-system, BlinkMacSystemFont, sans-serif;
            line-height: 1.6;
            color: var(--text-primary);
            background: linear-gradient(135deg, #f8fafc 0%, #e2e8f0 100%);
            min-height: 100vh;
        }
        
        .container {
            max-width: 1400px;
            margin: 0 auto;
            padding: var(--spacing-md);
        }
        
        /* Header */
        .header {
            background: var(--bg-white);
            border-radius: var(--border-radius-lg);
            padding: var(--spacing-xl);
            margin-bottom: var(--spacing-lg);
            text-align: center;
            box-shadow: var(--shadow-md);
            border: 1px solid #e2e8f0;
        }
        
        .header h1 {
            background: linear-gradient(135deg, var(--primary-color), var(--secondary-color), var(--accent-color));
            background-size: 200% 200%;
            -webkit-background-clip: text;
            -webkit-text-fill-color: transparent;
            background-clip: text;
            font-size: clamp(2rem, 5vw, 3.5rem);
            font-weight: 700;
            margin-bottom: var(--spacing-sm);
            animation: gradientShift 4s ease-in-out infinite;
        }
        
        @keyframes gradientShift {
            0%, 100% { background-position: 0% 50%; }
            50% { background-position: 100% 50%; }
        }
        
        .header p {
            color: var(--text-secondary);
            font-size: 1.3rem;
            font-weight: 400;
        }
        
        /* Progress bar */
        .progress-container {
            width: 100%;
            height: 8px;
            background: var(--bg-lighter);
            border-radius: 4px;
            margin-top: var(--spacing-md);
            overflow: hidden;
        }
        
        .progress-fill {
            height: 100%;
            background: linear-gradient(135deg, var(--success-color), var(--primary-color));
            border-radius: 4px;
            transition: width 0.8s ease;
            animation: progressPulse 2s ease-in-out infinite;
        }
        
        @keyframes progressPulse {
            0%, 100% { opacity: 1; }
            50% { opacity: 0.8; }
        }
        
        /* Navigation */
        .navigation {
            display: flex;
            gap: var(--spacing-sm);
            margin-bottom: var(--spacing-lg);
            flex-wrap: wrap;
            justify-content: center;
        }
        
        .nav-btn {
            background: linear-gradient(135deg, var(--bg-white), var(--bg-light));
            border: 2px solid #e2e8f0;
            border-radius: var(--border-radius);
            padding: var(--spacing-sm) var(--spacing-md);
            font-weight: 500;
            text-decoration: none;
            color: var(--text-primary);
            transition: all 0.3s ease;
            cursor: pointer;
            display: flex;
            align-items: center;
            gap: var(--spacing-xs);
        }
        
        .nav-btn:hover {
            transform: translateY(-2px);
            border-color: var(--primary-color);
            box-shadow: var(--shadow-md);
        }
        
        .nav-btn.active {
            background: linear-gradient(135deg, var(--primary-color), var(--secondary-color));
            color: white;
            border-color: var(--primary-color);
            box-shadow: var(--shadow-md);
        }
        
        /* Content sections */
        .content-section {
            background: var(--bg-white);
            border-radius: var(--border-radius-lg);
            padding: var(--spacing-xl);
            margin-bottom: var(--spacing-lg);
            box-shadow: var(--shadow-md);
            border: 1px solid #e2e8f0;
        }
        
        .section-title {
            background: linear-gradient(135deg, var(--info-color), var(--primary-color));
            -webkit-background-clip: text;
            -webkit-text-fill-color: transparent;
            background-clip: text;
            font-size: 2.5rem;
            font-weight: 700;
            margin-bottom: var(--spacing-lg);
            position: relative;
            padding-bottom: var(--spacing-sm);
        }
        
        .section-title::after {
            content: '';
            position: absolute;
            bottom: 0;
            left: 0;
            width: 60px;
            height: 4px;
            background: linear-gradient(135deg, var(--info-color), var(--primary-color));
            border-radius: 2px;
            animation: expandWidth 0.8s ease-out 0.3s both;
        }
        
        @keyframes expandWidth {
            from { width: 0; }
            to { width: 60px; }
        }
        
        /* Subsections */
        .subsection {
            margin-bottom: var(--spacing-lg);
            padding: var(--spacing-lg);
            background: var(--bg-light);
            border-radius: var(--border-radius);
            border: 1px solid #e2e8f0;
            transition: all 0.3s ease;
        }
        
        .subsection:hover {
            transform: translateY(-2px);
            box-shadow: var(--shadow-md);
            background: var(--bg-white);
        }
        
        .subsection h3 {
            color: var(--text-primary);
            margin-bottom: var(--spacing-md);
            font-size: 1.5rem;
            font-weight: 600;
            display: flex;
            align-items: center;
            gap: var(--spacing-xs);
        }
        
        .subsection h3::before {
            content: '';
            width: 4px;
            height: 24px;
            background: linear-gradient(135deg, var(--success-color), #00f2fe);
            border-radius: 2px;
        }
        
        .subsection p {
            color: var(--text-secondary);
            margin-bottom: 1rem;
            line-height: 1.7;
        }
        
        .subsection ul {
            color: var(--text-secondary);
            padding-left: 1.5rem;
        }
        
        .subsection li {
            margin-bottom: 0.5rem;
        }
        
        /* Tables */
        .clinical-table {
            width: 100%;
            border-collapse: separate;
            border-spacing: 0;
            margin: var(--spacing-md) 0;
            background: var(--bg-white);
            border-radius: var(--border-radius);
            overflow: hidden;
            box-shadow: var(--shadow-sm);
            border: 1px solid #e2e8f0;
        }
        
        .clinical-table th {
            background: linear-gradient(135deg, var(--info-color), var(--primary-color));
            color: white;
            padding: var(--spacing-md);
            text-align: left;
            font-weight: 600;
            font-size: 0.95rem;
            text-transform: uppercase;
            letter-spacing: 0.5px;
        }
        
        .clinical-table td {
            padding: var(--spacing-md);
            border-bottom: 1px solid #f1f5f9;
            transition: all 0.3s ease;
            color: var(--text-primary);
        }
        
        .clinical-table tbody tr:hover {
            background: #f8fafc;
        }
        
        .clinical-table tbody tr:last-child td {
            border-bottom: none;
        }
        
        /* Highlight boxes */
        .highlight-box {
            background: linear-gradient(135deg, #fff7ed, #fed7aa);
            border: 2px solid var(--warning-color);
            border-radius: var(--border-radius);
            padding: var(--spacing-lg);
            margin: var(--spacing-md) 0;
            position: relative;
            box-shadow: var(--shadow-sm);
        }
        
        .highlight-box::before {
            content: 'üí°';
            position: absolute;
            top: -12px;
            left: var(--spacing-md);
            background: var(--bg-white);
            padding: 0 var(--spacing-xs);
            font-size: 1.2rem;
        }
        
        .highlight-box h4 {
            color: var(--warning-color);
            margin-bottom: var(--spacing-sm);
            font-weight: 600;
        }
        
        /* Therapy comparison */
        .therapy-comparison {
            display: grid;
            grid-template-columns: 1fr 1fr;
            gap: var(--spacing-lg);
            margin: var(--spacing-lg) 0;
        }
        
        .therapy-card {
            background: var(--bg-white);
            border: 2px solid var(--primary-color);
            border-radius: var(--border-radius);
            padding: var(--spacing-lg);
            transition: all 0.3s ease;
            position: relative;
            overflow: hidden;
        }
        
        .therapy-card::before {
            content: '';
            position: absolute;
            top: 0;
            left: 0;
            right: 0;
            height: 4px;
            background: linear-gradient(135deg, var(--primary-color), var(--secondary-color));
        }
        
        .therapy-card:hover {
            transform: translateY(-4px);
            box-shadow: var(--shadow-lg);
            border-color: var(--secondary-color);
        }
        
        .therapy-card h4 {
            color: var(--primary-color);
            margin-bottom: var(--spacing-md);
            font-size: 1.3rem;
            font-weight: 600;
        }
        
        .therapy-badge {
            background: linear-gradient(135deg, var(--success-color), #00f2fe);
            color: white;
            padding: var(--spacing-xs) var(--spacing-sm);
            border-radius: 8px;
            display: inline-block;
            font-size: 0.8rem;
            font-weight: 600;
            margin: 2px;
        }
        
        .therapy-badge.ert {
            background: linear-gradient(135deg, var(--primary-color), var(--secondary-color));
        }
        
        .therapy-badge.chaperon {
            background: linear-gradient(135deg, var(--success-color), #00f2fe);
        }
        
        /* Treatment goals */
        .treatment-goals {
            background: var(--bg-light);
            border-radius: var(--border-radius);
            padding: var(--spacing-lg);
            margin: var(--spacing-md) 0;
            border: 1px solid #e2e8f0;
        }
        
        .treatment-goals h4 {
            color: var(--info-color);
            margin-bottom: var(--spacing-md);
            font-weight: 600;
            text-align: center;
        }
        
        .goals-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(200px, 1fr));
            gap: var(--spacing-sm);
        }
        
        .goal-item {
            background: var(--bg-white);
            border: 2px solid var(--success-color);
            border-radius: var(--border-radius);
            padding: var(--spacing-md);
            text-align: center;
            transition: all 0.3s ease;
        }
        
        .goal-item:hover {
            transform: translateY(-2px);
            box-shadow: var(--shadow-md);
            border-color: var(--primary-color);
        }
        
        .goal-item h5 {
            color: var(--success-color);
            margin-bottom: var(--spacing-xs);
            font-weight: 600;
        }
        
        /* Monitoring schedule */
        .monitoring-timeline {
            background: var(--bg-light);
            border-radius: var(--border-radius);
            padding: var(--spacing-lg);
            margin: var(--spacing-md) 0;
            border: 1px solid #e2e8f0;
        }
        
        .timeline-item {
            display: flex;
            align-items: center;
            margin: var(--spacing-md) 0;
            position: relative;
        }
        
        .timeline-item::before {
            content: '';
            position: absolute;
            left: 20px;
            top: 40px;
            bottom: -20px;
            width: 2px;
            background: var(--primary-color);
        }
        
        .timeline-item:last-child::before {
            display: none;
        }
        
        .timeline-marker {
            width: 40px;
            height: 40px;
            background: linear-gradient(135deg, var(--primary-color), var(--secondary-color));
            border-radius: 50%;
            display: flex;
            align-items: center;
            justify-content: center;
            color: white;
            font-weight: bold;
            margin-right: var(--spacing-md);
            position: relative;
            z-index: 2;
        }
        
        .timeline-content {
            flex: 1;
            background: var(--bg-white);
            padding: var(--spacing-md);
            border-radius: var(--border-radius);
            border: 1px solid #e2e8f0;
        }
        
        .timeline-content h5 {
            color: var(--primary-color);
            margin-bottom: var(--spacing-xs);
            font-weight: 600;
        }
        
        /* Completion badge */
        .completion-badge {
            background: linear-gradient(135deg, var(--success-color), #00f2fe);
            color: white;
            padding: var(--spacing-md) var(--spacing-lg);
            border-radius: 50px;
            display: inline-block;
            font-weight: 600;
            margin: var(--spacing-md) 0;
            box-shadow: var(--shadow-md);
            animation: completionPulse 2s ease-in-out infinite;
        }
        
        @keyframes completionPulse {
            0%, 100% { transform: scale(1); }
            50% { transform: scale(1.05); }
        }
        
        /* Final summary */
        .final-summary {
            background: linear-gradient(135deg, #f0f9ff, #e0f2fe);
            border: 2px solid var(--info-color);
            border-radius: var(--border-radius-lg);
            padding: var(--spacing-xl);
            margin: var(--spacing-lg) 0;
            text-align: center;
            box-shadow: var(--shadow-md);
        }
        
        .final-summary h3 {
            color: var(--info-color);
            margin-bottom: var(--spacing-lg);
            font-size: 2rem;
            font-weight: 700;
        }
        
        .final-summary p {
            color: var(--text-secondary);
            font-size: 1.1rem;
            margin-bottom: var(--spacing-md);
        }
        
        /* Finish button */
        .finish-btn {
            background: linear-gradient(135deg, var(--success-color), var(--primary-color));
            color: white;
            border: none;
            padding: var(--spacing-lg) var(--spacing-xl);
            border-radius: var(--border-radius);
            font-size: 1.2rem;
            font-weight: 700;
            cursor: pointer;
            display: block;
            margin: var(--spacing-xl) auto 0;
            transition: all 0.3s cubic-bezier(0.4, 0, 0.2, 1);
            box-shadow: var(--shadow-lg);
            text-transform: uppercase;
            letter-spacing: 2px;
            position: relative;
            overflow: hidden;
        }
        
        .finish-btn::before {
            content: '';
            position: absolute;
            top: 0;
            left: -100%;
            width: 100%;
            height: 100%;
            background: linear-gradient(90deg, transparent, rgba(255,255,255,0.2), transparent);
            transition: left 0.5s;
        }
        
        .finish-btn:hover::before {
            left: 100%;
        }
        
        .finish-btn:hover {
            transform: translateY(-6px) scale(1.05);
            box-shadow: var(--shadow-lg);
        }
        
        .part-info {
            background: linear-gradient(135deg, #eff6ff, #dbeafe);
            border: 2px solid var(--info-color);
            border-radius: var(--border-radius);
            padding: var(--spacing-md);
            margin-bottom: var(--spacing-lg);
            text-align: center;
            box-shadow: var(--shadow-sm);
        }
        
        .part-info h3 {
            color: var(--info-color);
            margin-bottom: var(--spacing-sm);
        }
        
        .part-info p {
            color: var(--text-secondary);
        }
        
        /* Responsive design */
        @media (max-width: 768px) {
            .container {
                padding: var(--spacing-sm);
            }
            
            .header h1 {
                font-size: 2.5rem;
            }
            
            .header p {
                font-size: 1.1rem;
            }
            
            .navigation {
                flex-direction: column;
            }
            
            .nav-btn {
                width: 100%;
                text-align: center;
            }
            
            .content-section {
                padding: var(--spacing-md);
            }
            
            .section-title {
                font-size: 2rem;
            }
            
            .subsection {
                padding: var(--spacing-md);
            }
            
            .therapy-comparison {
                grid-template-columns: 1fr;
            }
            
            .goals-grid {
                grid-template-columns: 1fr;
            }
        }
        
        @media (max-width: 480px) {
            .header {
                padding: var(--spacing-md);
            }
            
            .header h1 {
                font-size: 2rem;
            }
            
            .section-title {
                font-size: 1.8rem;
            }
        }
        
        /* Animation stagger */
        .subsection {
            animation: fadeInStagger 0.6s ease-out both;
        }
        
        @keyframes fadeInStagger {
            from {
                opacity: 0;
                transform: translateY(20px);
            }
            to {
                opacity: 1;
                transform: translateY(0);
            }
        }
        
        .subsection:nth-child(1) { animation-delay: 0.1s; }
        .subsection:nth-child(2) { animation-delay: 0.2s; }
        .subsection:nth-child(3) { animation-delay: 0.3s; }
        .subsection:nth-child(4) { animation-delay: 0.4s; }
        .subsection:nth-child(5) { animation-delay: 0.5s; }
        .subsection:nth-child(6) { animation-delay: 0.6s; }
    </style>
</head>
<body>
    <div class="container">
        <div class="header">
            <h1>üíä Morbus Fabry</h1>
            <p>Teil 4: Therapie & Management</p>
            <div class="progress-container">
                <div class="progress-fill" id="progressBar" style="width: 100%"></div>
            </div>
        </div>

        <div class="part-info">
            <h3>üéØ Lerneinheit Teil 4 - Finale</h3>
            <p>Moderne Therapieoptionen und evidenzbasiertes Management des Morbus Fabry - von der Enzymersatztherapie bis zur personalisierten Medizin.</p>
        </div>

        <div class="navigation">
            <button class="nav-btn active">1. Therapieziele</button>
            <button class="nav-btn">2. Enzymersatztherapie</button>
            <button class="nav-btn">3. Chaperontherapie</button>
            <button class="nav-btn">4. Monitoring</button>
        </div>

        <div class="content-section">
            <h2 class="section-title">Therapie & Management</h2>

            <div class="subsection">
                <h3>Therapieziele und Grundprinzipien</h3>
                <p>Die Therapie des Morbus Fabry erfordert eine <strong>enge interdisziplin√§re Zusammenarbeit</strong> und ein multimodales Behandlungskonzept.</p>
                
                <div class="treatment-goals">
                    <h4>üéØ Prim√§re Therapieziele</h4>
                    <div class="goals-grid">
                        <div class="goal-item">
                            <h5>üõ°Ô∏è Organprotektion</h5>
                            <p style="font-size: 0.9em;">Verhinderung der Progression von Organmanifestationen</p>
                        </div>
                        <div class="goal-item">
                            <h5>üòå Symptomlinderung</h5>
                            <p style="font-size: 0.9em;">Reduktion von Schmerzen und GI-Beschwerden</p>
                        </div>
                        <div class="goal-item">
                            <h5>üìà Lebensqualit√§t</h5>
                            <p style="font-size: 0.9em;">Verbesserung der gesundheitsbezogenen Lebensqualit√§t</p>
                        </div>
                        <div class="goal-item">
                            <h5>‚è∞ Lebensverl√§ngerung</h5>
                            <p style="font-size: 0.9em;">Verl√§ngerung der Lebenserwartung</p>
                        </div>
                    </div>
                </div>
                
                <div class="highlight-box">
                    <h4>üè• Zentrums√ºberweisung empfohlen</h4>
                    <p>Nach best√§tigter Diagnose sollten Betroffene zur <strong>Eingangsuntersuchung und Therapieplanung</strong> an ein in der Diagnostik und Therapie erfahrenes Zentrum √ºberwiesen werden.</p>
                </div>
            </div>

            <div class="subsection">
                <h3>Enzymersatztherapie (ERT)</h3>
                <p>Seit 2001 steht mit der ERT eine <strong>kausale Behandlungsoption</strong> zur Verf√ºgung. Die gentechnologisch hergestellte Œ±-Galaktosidase A wird alle 14 Tage intraven√∂s infundiert.</p>
                
                <div class="therapy-comparison">
                    <div class="therapy-card">
                        <h4>üíâ Agalsidase alfa</h4>
                        <div style="margin: 15px 0;">
                            <span class="therapy-badge ert">Replagal¬Æ</span>
                            <span class="therapy-badge ert">0,2 mg/kg</span>
                            <span class="therapy-badge ert">HT-1080 Zellen</span>
                        </div>
                        <ul style="font-size: 0.9em;">
                            <li><strong>Dosierung:</strong> 0,2 mg/kg KG alle 14 Tage</li>
                            <li><strong>Herstellung:</strong> Humane Fibrosarkom-Zelllinie</li>
                            <li><strong>Infusionsdauer:</strong> 40 Minuten</li>
                            <li><strong>Antik√∂rper:</strong> ~24% der M√§nner</li>
                        </ul>
                    </div>
                    
                    <div class="therapy-card">
                        <h4>üíâ Agalsidase beta</h4>
                        <div style="margin: 15px 0;">
                            <span class="therapy-badge ert">Fabrazyme¬Æ</span>
                            <span class="therapy-badge ert">1,0 mg/kg</span>
                            <span class="therapy-badge ert">CHO-Zellen</span>
                        </div>
                        <ul style="font-size: 0.9em;">
                            <li><strong>Dosierung:</strong> 1,0 mg/kg KG alle 14 Tage</li>
                            <li><strong>Herstellung:</strong> Chinese Hamster Ovary Zellen</li>
                            <li><strong>Infusionsdauer:</strong> 4 Stunden</li>
                            <li><strong>Antik√∂rper:</strong> Mehrzahl in ersten 3 Monaten</li>
                        </ul>
                    </div>
                </div>
                
                <table class="clinical-table">
                    <thead>
                        <tr>
                            <th>Aspekt</th>
                            <th>Agalsidase alfa</th>
                            <th>Agalsidase beta</th>
                            <th>Klinische Relevanz</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>Wirksamkeit</strong></td>
                            <td>Gut dokumentiert</td>
                            <td>Gut dokumentiert</td>
                            <td>Keine klinisch relevanten Unterschiede</td>
                        </tr>
                        <tr>
                            <td><strong>Glykosylierung</strong></td>
                            <td>Human-√§hnlich</td>
                            <td>CHO-spezifisch</td>
                            <td>Unterschiedliche Muster</td>
                        </tr>
                        <tr>
                            <td><strong>Immunogenit√§t</strong></td>
                            <td>24% (‚ôÇ)</td>
                            <td>H√∂her (‚ôÇ)</td>
                            <td>Antik√∂rper k√∂nnen Wirkung mindern</td>
                        </tr>
                        <tr>
                            <td><strong>Praktikabilit√§t</strong></td>
                            <td>K√ºrzere Infusion</td>
                            <td>L√§ngere Infusion</td>
                            <td>Patientenpr√§ferenz ber√ºcksichtigen</td>
                        </tr>
                    </tbody>
                </table>
                
                <div class="highlight-box">
                    <h4>‚ö†Ô∏è Antik√∂rperproblematik</h4>
                    <p><strong>40% aller m√§nnlichen Patienten</strong> entwickeln neutralisierende Antik√∂rper, die mit h√∂herem Lyso-Gb3, gr√∂√üerer LVM und schlechterer Nierenfunktion assoziiert sind. Eine Immunmodulation kann erwogen werden.</p>
                </div>
            </div>

            <div class="subsection">
                <h3>Chaperontherapie mit Migalastat</h3>
                <p>Seit 2016 steht mit <strong>Migalastat (Galafold¬Æ)</strong> eine orale Behandlungsoption f√ºr Patienten mit "amenable" Genvarianten zur Verf√ºgung.</p>
                
                <div style="display: grid; grid-template-columns: 1fr 1fr; gap: 30px; margin: 20px 0;">
                    <div style="background: linear-gradient(135deg, #f0f9ff, #e0f2fe); padding: 20px; border-radius: 12px; border: 2px solid #0ea5e9;">
                        <h4 style="color: #0369a1; margin-bottom: 15px;">üß¨ Wirkmechanismus</h4>
                        <ul style="color: #075985; font-size: 0.9em;">
                            <li><strong>Pharmacological Chaperon:</strong> 1-Deoxygalactonojirimycin</li>
                            <li><strong>Stabilisierung:</strong> Fehlfaltung des AGLA-Proteins verhindern</li>
                            <li><strong>Transport:</strong> Verbesserter Transport zu Lysosomen</li>
                            <li><strong>Aktivit√§t:</strong> Erh√∂hte Enzymaktivit√§t in Lysosomen</li>
                        </ul>
                    </div>
                    
                    <div style="background: linear-gradient(135deg, #fef3c7, #fcd34d); padding: 20px; border-radius: 12px; border: 2px solid #f59e0b;">
                        <h4 style="color: #92400e; margin-bottom: 15px;">üìã Indikation & Dosierung</h4>
                        <ul style="color: #92400e; font-size: 0.9em;">
                            <li><strong>Alter:</strong> ‚â•12 Jahre (‚â•45 kg KG)</li>
                            <li><strong>Dosierung:</strong> 123 mg jeden 2. Tag oral</li>
                            <li><strong>Voraussetzung:</strong> "Amenable" Genvariante</li>
                            <li><strong>Test:</strong> In-vitro Amenability Assay</li>
                        </ul>
                    </div>
                </div>
                
                <div class="therapy-card" style="margin: 20px 0;">
                    <h4>üéØ "Amenable" Varianten</h4>
                    <p style="margin-bottom: 15px;">Nur bestimmte Missense-Varianten sprechen auf Migalastat an. Die aktuelle Liste finden Sie unter:</p>
                    <div style="text-align: center; margin: 15px 0;">
                        <span class="therapy-badge chaperon">www.galafoldamenabilitytable.com</span>
                    </div>
                    <p style="font-size: 0.9em; color: var(--text-muted);">Die Amenability-Testung ist vor Therapiebeginn zwingend erforderlich!</p>
                </div>
                
                <table class="clinical-table" style="margin-top: 20px;">
                    <thead>
                        <tr>
                            <th>Vergleichsaspekt</th>
                            <th>ERT</th>
                            <th>Migalastat</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>Applikation</strong></td>
                            <td>IV alle 14 Tage</td>
                            <td>Oral jeden 2. Tag</td>
                        </tr>
                        <tr>
                            <td><strong>Patienteneignung</strong></td>
                            <td>Alle Varianten</td>
                            <td>Nur "amenable" Varianten</td>
                        </tr>
                        <tr>
                            <td><strong>Immunogenit√§t</strong></td>
                            <td>Antik√∂rperrisiko</td>
                            <td>Kein Antik√∂rperrisiko</td>
                        </tr>
                        <tr>
                            <td><strong>Gewebe-Penetration</strong></td>
                            <td>Limitiert</td>
                            <td>Bessere Penetration</td>
                        </tr>
                    </tbody>
                </table>
            </div>

            <div class="subsection">
                <h3>Symptomatische und adjuvante Therapien</h3>
                <p>Neben der kausalen Therapie sind <strong>symptomatische Behandlungen</strong> essentiell f√ºr die umfassende Betreuung von Fabry-Patienten.</p>
                
                <div style="display: grid; grid-template-columns: repeat(auto-fit, minmax(300px, 1fr)); gap: 20px; margin: 20px 0;">
                    <div style="background: linear-gradient(135deg, #fef2f2, #fecaca); padding: 20px; border-radius: 12px; border: 2px solid #ef4444;">
                        <h4 style="color: #dc2626; margin-bottom: 15px;">‚ö° Fabry-Schmerzen</h4>
                        <ul style="color: #7f1d1d; font-size: 0.9em;">
                            <li><strong>Antikonvulsiva:</strong> Gabapentin, Pregabalin</li>
                            <li><strong>Antidepressiva:</strong> Duloxetin, Amitriptylin</li>
                            <li><strong>Akutschmerz:</strong> NSAR, Metamizol</li>
                            <li><strong>Vermeidung:</strong> Triggerfaktoren (Hitze, Stress)</li>
                        </ul>
                    </div>
                    
                    <div style="background: linear-gradient(135deg, #f0f9ff, #e0f2fe); padding: 20px; border-radius: 12px; border: 2px solid #0ea5e9;">
                        <h4 style="color: #0369a1; margin-bottom: 15px;">ü´Ä Kardiale Therapie</h4>
                        <ul style="color: #075985; font-size: 0.9em;">
                            <li><strong>ACE-Hemmer/ARB:</strong> Kardio- und Nephroprotektiv</li>
                            <li><strong>Betablocker:</strong> Bei Arrhythmien/Hypertrophie</li>
                            <li><strong>ICD/CRT:</strong> Bei malignen Arrhythmien</li>
                            <li><strong>Antikoagulation:</strong> Bei Vorhofflimmern</li>
                        </ul>
                    </div>
                    
                    <div style="background: linear-gradient(135deg, #fefce8, #fef3c7); padding: 20px; border-radius: 12px; border: 2px solid #eab308;">
                        <h4 style="color: #a16207; margin-bottom: 15px;">ü´Å Nephroprotektive Therapie</h4>
                        <ul style="color: #92400e; font-size: 0.9em;">
                            <li><strong>ACE-Hemmer/ARB:</strong> Proteinurie-Reduktion</li>
                            <li><strong>SGLT2-Inhibitoren:</strong> Zus√§tzlicher Benefit</li>
                            <li><strong>Blutdruckkontrolle:</strong> <130/80 mmHg</li>
                            <li><strong>Dialyse/Transplantation:</strong> Bei Nierenversagen</li>
                        </ul>
                    </div>
                    
                    <div style="background: linear-gradient(135deg, #f0fdf4, #dcfce7); padding: 20px; border-radius: 12px; border: 2px solid #22c55e;">
                        <h4 style="color: #15803d; margin-bottom: 15px;">üß† Neurologische Therapie</h4>
                        <ul style="color: #166534; font-size: 0.9em;">
                            <li><strong>Schlaganfallprophylaxe:</strong> Thrombozytenaggregationshemmer</li>
                            <li><strong>Epilepsie:</strong> Antikonvulsiva</li>
                            <li><strong>Depression:</strong> SSRI/SNRI</li>
                            <li><strong>Psychotherapie:</strong> Krankheitsbew√§ltigung</li>
                        </ul>
                    </div>
                </div>
                
                <div class="highlight-box">
                    <h4>üë©‚Äç‚öïÔ∏è Besonderheiten bei Frauen</h4>
                    <p><strong>Therapieindikation bei Frauen</strong> anhand gleicher Kriterien wie bei M√§nnern stellen! W√§hrend der Schwangerschaft ist die Indikation zur ERT vorsichtig und streng zu stellen (nach 1. Trimenon).</p>
                </div>
            </div>

            <div class="subsection">
                <h3>Therapiemonitoring und Verlaufskontrolle</h3>
                <p>Regelm√§√üige Kontrollen sind essentiell zur <strong>√úberwachung des Therapieerfolgs</strong> und zur fr√ºhzeitigen Erkennung von Komplikationen.</p>
                
                <div class="monitoring-timeline">
                    <h4 style="color: var(--info-color); text-align: center; margin-bottom: 20px;">üìÖ Monitoring-Schedule</h4>
                    
                    <div class="timeline-item">
                        <div class="timeline-marker">3M</div>
                        <div class="timeline-content">
                            <h5>Erste Verlaufskontrolle</h5>
                            <p style="font-size: 0.9em;">Vertr√§glichkeit der Therapie, Lyso-Gb3, Basisparameter</p>
                        </div>
                    </div>
                    
                    <div class="timeline-item">
                        <div class="timeline-marker">6M</div>
                        <div class="timeline-content">
                            <h5>Erweiterte Kontrolle</h5>
                            <p style="font-size: 0.9em;">Organfunktion, Biomarker, Nebenwirkungen, Antik√∂rper</p>
                        </div>
                    </div>
                    
                    <div class="timeline-item">
                        <div class="timeline-marker">12M</div>
                        <div class="timeline-content">
                            <h5>Jahresuntersuchung</h5>
                            <p style="font-size: 0.9em;">Vollst√§ndige Organevaluation, Therapieadjustierung</p>
                        </div>
                    </div>
                    
                    <div class="timeline-item">
                        <div class="timeline-marker">‚àû</div>
                        <div class="timeline-content">
                            <h5>Lebenslange Nachsorge</h5>
                            <p style="font-size: 0.9em;">12-monatige Kontrollen mit kompletter Organevaluation</p>
                        </div>
                    </div>
                </div>
                
                <table class="clinical-table" style="margin-top: 20px;">
                    <thead>
                        <tr>
                            <th>Parameter</th>
                            <th>Kontrolle</th>
                            <th>Zielwerte</th>
                            <th>Bedeutung</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>Lyso-Gb3</strong></td>
                            <td>Alle 6 Monate</td>
                            <td>Reduktion/Stabilisierung</td>
                            <td>Therapieresponse</td>
                        </tr>
                        <tr>
                            <td><strong>eGFR</strong></td>
                            <td>Alle 6 Monate</td>
                            <td>Stabilisierung</td>
                            <td>Nephroprotektiv</td>
                        </tr>
                        <tr>
                            <td><strong>Proteinurie</strong></td>
                            <td>Alle 6 Monate</td>
                            <td><300 mg/g Kreatinin</td>
                            <td>Nierenfunktion</td>
                        </tr>
                        <tr>
                            <td><strong>LVMI</strong></td>
                            <td>J√§hrlich</td>
                            <td>Stabilisierung/Reduktion</td>
                            <td>Kardioprotektiv</td>
                        </tr>
                        <tr>
                            <td><strong>Schmerz-Scores</strong></td>
                            <td>Alle 3 Monate</td>
                            <td>Reduktion</td>
                            <td>Symptomkontrolle</td>
                        </tr>
                    </tbody>
                </table>
            </div>

            <div class="subsection">
                <h3>Prognose und Zukunftsperspektiven</h3>
                <p>Mit moderner Therapie hat sich die <strong>Prognose des Morbus Fabry deutlich verbessert</strong>, jedoch bleibt die fr√ºhzeitige Diagnose und Behandlung entscheidend.</p>
                
                <div style="display: grid; grid-template-columns: 1fr 1fr; gap: 30px; margin: 20px 0;">
                    <div style="background: linear-gradient(135deg, #dcfce7, #86efac); padding: 20px; border-radius: 12px; border: 2px solid #22c55e;">
                        <h4 style="color: #15803d; margin-bottom: 15px;">‚úÖ Therapieerfolge</h4>
                        <ul style="color: #166534; font-size: 0.9em;">
                            <li><strong>Organprotektion:</strong> Verlangsamte Progression</li>
                            <li><strong>Symptomlinderung:</strong> Verbesserte Lebensqualit√§t</li>
                            <li><strong>Langzeitdaten:</strong> >20 Jahre Erfahrung</li>
                            <li><strong>Fr√ºhe Therapie:</strong> Bessere Langzeitprognose</li>
                        </ul>
                    </div>
                    
                    <div style="background: linear-gradient(135deg, #fef3c7, #fcd34d); padding: 20px; border-radius: 12px; border: 2px solid #f59e0b;">
                        <h4 style="color: #92400e; margin-bottom: 15px;">üî¨ Zukunftsperspektiven</h4>
                        <ul style="color: #92400e; font-size: 0.9em;">
                            <li><strong>Gentherapie:</strong> In klinischer Entwicklung</li>
                            <li><strong>Substratreduktion:</strong> Neue Ans√§tze</li>
                            <li><strong>Biomarker:</strong> Verbesserte Diagnostik</li>
                            <li><strong>Personalisierte Medizin:</strong> Variantenspezifisch</li>
                        </ul>
                    </div>
                </div>
                
                <div class="final-summary">
                    <h3>üéØ Fazit f√ºr die Praxis</h3>
                    <p><strong>Morbus Fabry ist eine behandelbare Multisystemerkrankung!</strong></p>
                    <p>Fr√ºhe Diagnose und rechtzeitiger Therapiebeginn sind entscheidend f√ºr die Prognose. Die interdisziplin√§re Betreuung in erfahrenen Zentren verbessert die Langzeitergebnisse erheblich.</p>
                    <div class="completion-badge">
                        üèÜ Lernmodul erfolgreich abgeschlossen!
                    </div>
                </div>
            </div>
        </div>

        <button class="finish-btn" onclick="window.open('about:blank')">
            üéâ Lernmodul abschlie√üen
        </button>
    </div>

    <script>
        // Progress tracking - start at 100% for final module
        let currentProgress = 100;
        
        function updateProgress(progress) {
            const progressBar = document.getElementById('progressBar');
            progressBar.style.width = progress + '%';
        }
        
        // Navigation functionality
        document.querySelectorAll('.nav-btn').forEach((btn, index) => {
            btn.addEventListener('click', function() {
                // Remove active class from all buttons
                document.querySelectorAll('.nav-btn').forEach(b => b.classList.remove('active'));
                
                // Add active class to clicked button
                this.classList.add('active');
                
                // Update progress based on section (80-100% range for part 4)
                updateProgress(80 + (index + 1) * 5);
            });
        });
        
        // Scroll animations
        const observerOptions = {
            threshold: 0.1,
            rootMargin: '0px 0px -50px 0px'
        };
        
        const observer = new IntersectionObserver((entries) => {
            entries.forEach(entry => {
                if (entry.isIntersecting) {
                    entry.target.style.opacity = '1';
                    entry.target.style.transform = 'translateY(0)';
                }
            });
        }, observerOptions);
        
        document.querySelectorAll('.subsection').forEach(section => {
            observer.observe(section);
        });
        
        // Interactive hover effects for therapy cards
        document.querySelectorAll('.therapy-card').forEach(card => {
            card.addEventListener('mouseenter', function() {
                this.style.transform = 'translateY(-6px)';
                this.style.borderColor = 'var(--secondary-color)';
            });
            
            card.addEventListener('mouseleave', function() {
                this.style.transform = 'translateY(0)';
                this.style.borderColor = 'var(--primary-color)';
            });
        });
        
        // Interactive hover effects for goal items
        document.querySelectorAll('.goal-item').forEach(item => {
            item.addEventListener('mouseenter', function() {
                this.style.transform = 'translateY(-4px)';
                this.style.borderColor = 'var(--primary-color)';
            });
            
            item.addEventListener('mouseleave', function() {
                this.style.transform = 'translateY(0)';
                this.style.borderColor = 'var(--success-color)';
            });
        });
        
        // Timeline item interactions
        document.querySelectorAll('.timeline-item').forEach(item => {
            item.addEventListener('mouseenter', function() {
                const marker = this.querySelector('.timeline-marker');
                const content = this.querySelector('.timeline-content');
                marker.style.transform = 'scale(1.1)';
                content.style.background = 'var(--bg-lighter)';
            });
            
            item.addEventListener('mouseleave', function() {
                const marker = this.querySelector('.timeline-marker');
                const content = this.querySelector('.timeline-content');
                marker.style.transform = 'scale(1)';
                content.style.background = 'var(--bg-white)';
            });
        });
        
        // Completion celebration effect
        function celebrateCompletion() {
            const badge = document.querySelector('.completion-badge');
            if (badge) {
                badge.style.animation = 'completionPulse 0.5s ease-in-out 3';
            }
        }
        
        // Trigger celebration when final summary comes into view
        const finalSummary = document.querySelector('.final-summary');
        if (finalSummary) {
            const celebrationObserver = new IntersectionObserver((entries) => {
                entries.forEach(entry => {
                    if (entry.isIntersecting) {
                        setTimeout(celebrateCompletion, 500);
                    }
                });
            }, { threshold: 0.5 });
            
            celebrationObserver.observe(finalSummary);
        }
    </script>
</body>
</html>
